Overview

Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer
Phase:
Phase 2
Details
Lead Sponsor:
Southern Illinois University
Collaborators:
Genentech, Inc.
OSI Pharmaceuticals
Treatments:
Cisplatin
Erlotinib Hydrochloride